R&D
Collaborations
CELL CULTURE LAB
IN COLLABORATION
WITH BIONEST
Lazuline Biotech has established a cell culture laboratory in collaboration with BioNest (Bio incubators Nurturing Entrepreneurship for Scaling Technologies) at Hyderabad Central University.Bionest is a Government of India Initiative as part of “Make in India”.
The objective is to take up product testing and validation on different stem cell lines and other mammalian cells using the company’s recombinant Human Serum Albumin (rHSA). This enables continuous improvements to ensure our market positioning for global clients. Results from the facility are helping us constantly set up new product performance benchmarks, improvements, and qualifications, feeding back to our manufacturing and QA/QC protocols. In addition, we are able to test and conduct a performance evaluation of products from batches before our customers’ usage, thus ensuring overall customer satisfaction and specific customizations as and when required.
Efforts are on to further the goals of this facility to expand and broad base our initiatives towards forward integration of our product lines, benchmark with alternative and competitive products to generate research-based data and publications.
PARTNERING WITH NATIONAL CHENG KUNG UNIVERSITY, TAIWAN FOR DRUG DEVELOPMENT
Lazuline Biotech has entered into a strategic agreement with National Cheng Kung University, Taiwan (NCKU) to advance the drug and vaccine development for Alzheimer’s Disease and cancer. This marks a significant milestone in international collaborations.
This association is in light of the discovery of a small drug peptide named “Zfra” or “Zffi” by distinguished Professor Nan-Shan Chang at the Institute of Molecular Medicine of NCKU. The research teams from both NCKU and LBPL will work together on Zffi to develop drugs and vaccines and are expecting the clinical trials to be initiated in India between 2022 and 2023 considering the completion of significant R&D work.
For the development of a new drug, the effort from bench work to clinical trials is enormous and is likely to take a considerable amount of time. The joint effort between Lazuline and NCKU can accelerate and streamline the drug development process. We hope to be a major contributor to the advancement of Alzheimer’s cure.
